EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Histopathological response to chemotherapy and survival of mucinous type gastric cancer

Irene A Caspers iD, Astrid E Slagter, Pauline A J Vissers, Martha Lopez-Yurda iD, Laurens V Beerepoot, Jelle P Ruurda, Grard A P Nieuwenhuijzen iD, Suzanne S Gisbertz iD, Mark I van Berge Henegouwen, Henk H Hartgrink, Danny Goudkade, Liudmila L Kodach und 5 weitere

JNCI: Journal of the National Cancer Institute · 2025

DOI: 10.1093/jnci/djae227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JNCI: Journal of the National Cancer Institute, 2025. Verfasst von Irene A Caspers und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Mucinous, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Data on the clinicopathological characteristics of mucinous gastric cancer (muc-GC) are limited. This study compares the clinical outcome and response to chemotherapy between patients with resectable muc-GC, intestinal (int-GC), and diffuse (dif-GC) gastric cancer.

Methods

Patients from the D1/D2 study or the CRITICS trial were included in exploratory surgery-alone (SAtest) or chemotherapy test (CTtest) cohorts. Real-world data from the Netherlands Cancer Registry on patients treated between with surgery alone (SAvalidation) and receiving preoperative chemotherapy with or without postoperative treatment (CTvalidation) were used for validation. Histopathological subtypes were extracted from pathology reports filed in the Dutch Pathology Registry and correlated with tumor regression grade (TRG) and relative survival (RS).

Results

In the SAtest (n = 549) and SAvalidation (n = 8062) cohorts, muc-GC patients had a 5-year RS of 39% and 31%, similar to or slightly better than dif-GC (43% and 29%, P = .52 and P = .011), but worse than int-GC (55% and 42%, P = .11 and P < .001). In the CTtest (n = 651) and CTvalidation (n = 2889) cohorts, muc-GC showed favorable TRG (38% and 44% (near-) complete response) compared with int-GC (26% and 35%) and dif-GC (10% and 28%, P < .001 and P = .005). The 5-year RS in the CTtest and CTvalidation cohorts for muc-GC (53% and 48%) and int-GC (58% and 59%) was significantly better compared with dif-GC (35% and 38%, P = .004 and P < .001).

Conclusion

Recognizing and incorporating muc-GC into treatment decision-making of resectable GC can lead to more personalized and effective approaches, given its favorable response to preoperative chemotherapy in relation to int-GC and dif-GC and its favorable prognostic outcomes in relation to dif-GC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Stomach NeoplasmsAdenocarcinoma, MucinousAntineoplastic Combined Chemotherapy ProtocolsHumansMaleFemaleMiddle AgedAgedNetherlandsRegistriesTreatment OutcomeAdultChemotherapy, AdjuvantGastrectomy

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
  • Department of Pathology, Amsterdam University Medical Center, Cancer Center Amsterdam, Amsterdam, the Netherlands.
  • Department of Radiation Oncology, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.
  • Department of Research and Development, Netherlands Comprehensive Cancer Organization (IKNL), Utrecht, the Netherlands.
  • Department of Surgery, Radboud University Medical Center, Nijmegen, the Netherlands.
  • Department of Biometrics, Netherlands Cancer Institute, Antoni van Leeuwenhoek, Amsterdam, the Netherlands.

ORCID-Profile: Irene A Caspers, Martha Lopez-Yurda, Grard A P Nieuwenhuijzen, Suzanne S Gisbertz, Nicole C T van Grieken

Zitieren

APA

Caspers, I. A., Slagter, A. E., Vissers, P. A. J., Lopez-Yurda, M., Beerepoot, L. V., Ruurda, J. P., Nieuwenhuijzen, G. A. P., Gisbertz, S. S., van Berge Henegouwen, M. I., Hartgrink, H. H., Goudkade, D., Kodach, L. L., van Sandick, J. W., Verheij, M., Verhoeven, R. H. A., Cats, A., & van Grieken, N. C. T. (2025). Histopathological response to chemotherapy and survival of mucinous type gastric cancer. JNCI: Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djae227

Vancouver

Caspers IA, Slagter AE, Vissers PAJ, Lopez-Yurda M, Beerepoot LV, Ruurda JP, et al. Histopathological response to chemotherapy and survival of mucinous type gastric cancer. JNCI: Journal of the National Cancer Institute. 2025. doi:10.1093/jnci/djae227

BibTeX
@article{Caspers2025,
  author = {Caspers, Irene A and Slagter, Astrid E and Vissers, Pauline A J and Lopez-Yurda, Martha and Beerepoot, Laurens V and Ruurda, Jelle P and Nieuwenhuijzen, Grard A P and Gisbertz, Suzanne S and van Berge Henegouwen, Mark I and Hartgrink, Henk H and Goudkade, Danny and Kodach, Liudmila L and van Sandick, Johanna W and Verheij, Marcel and Verhoeven, Rob H A and Cats, Annemieke and van Grieken, Nicole C T},
  title = {Histopathological response to chemotherapy and survival of mucinous type gastric cancer},
  journal = {JNCI: Journal of the National Cancer Institute},
  year = {2025},
  doi = {10.1093/jnci/djae227}
}
Kostenlos starten →